This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hermans, I. F. Articles by Cerundolo, V. Search for Related Content PubMed PubMed Citation Articles by Hermans, I. F. Articles by Cerundolo, V.

Synergistic Effect of Metronomic Dosing of Cyclophosphamide Combined with Specific Antitumor Immunotherapy in a Murine Melanoma Model

¹ Tumour Immunology Unit,
² Molecular Oncology Laboratory, Cancer Research UK, University of Oxford, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Immunotherapy could be combined with conventional chemotherapeutic modalities aimed at reducing tumor burden. Such combination therapy may be most useful when "metronomic" doses of antineoplastic drugs are used, thereby potentially avoiding some of the immunosuppressive effects of these drugs. Recent studies have shown that some conventional antineoplastic drugs can be exploited for antiangiogenic capacities, a strategy that requires drugs to be administered at regular intervals. We therefore investigated whether such metronomic therapy with the alkylating agent cyclophosphamide (CTX) could be effectively combined with immunotherapy eliciting tumor-reactive CTLs. An immunization protocol using injection of recombinant DNA followed by injection of recombinant modified vaccinia virus Ankara strain was used to initiate a specific CTL response in mice capable of providing resistance to challenge with the murine melanoma B16.F10. Combining this immunotherapeutic regime with metronomic delivery of CTX resulted in antitumor activity that was dramatically enhanced over either treatment administered alone and was also significantly greater than combining immunotherapy with CTX administered by a maximum tolerated dose regime. Whereas both metronomic and maximum tolerated dose delivery of CTX did cause deletion of proliferating tumor-specific CTLs in the blood, this deletion occurred with slower kinetics with the metronomic schedule. Further analysis showed that metronomic CTX treatment did not delete cells with low expression of CD43, a "memory" phenotype, and that these cells maintained potent restimulatory capacity. The combination of immunotherapy and metronomic CTX therapy may be well suited to clinical management of cancer.

This article has been cited by other articles:

				L. G. Daenen, Y. Shaked, S. Man, P. Xu, E. E. Voest, R. M. Hoffman, D. J. Chaplin, and R. S. Kerbel Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models Mol. Cancer Ther., October 1, 2009; 8(10): 2872 - 2881. [Abstract] [Full Text] [PDF]

				W. Cruz-Munoz, S. Man, and R. S. Kerbel Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens Clin. Cancer Res., August 1, 2009; 15(15): 4867 - 4874. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]

				P. Rietschel, J. D. Wolchok, S. Krown, S. Gerst, A. A. Jungbluth, K. Busam, K. Smith, I. Orlow, K. Panageas, and P. B. Chapman Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma J. Clin. Oncol., May 10, 2008; 26(14): 2299 - 2304. [Abstract] [Full Text] [PDF]

				R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, et al. Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4487 - 4494. [Abstract] [Full Text] [PDF]

				L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al. Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration Clin. Cancer Res., January 15, 2007; 13(2): 644 - 653. [Abstract] [Full Text] [PDF]

				A. Bottini, D. Generali, M. P. Brizzi, S. B. Fox, A. Bersiga, S. Bonardi, G. Allevi, S. Aguggini, G. Bodini, M. Milani, et al. Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients J. Clin. Oncol., August 1, 2006; 24(22): 3623 - 3628. [Abstract] [Full Text] [PDF]

				S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors. Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098. [Abstract] [Full Text] [PDF]

				Y. Shaked, U. Emmenegger, S. Man, D. Cervi, F. Bertolini, Y. Ben-David, and R. S. Kerbel Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Blood, November 1, 2005; 106(9): 3058 - 3061. [Abstract] [Full Text] [PDF]

				Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C. R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R. S. Kerbel Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy Cancer Res., August 15, 2005; 65(16): 7045 - 7051. [Abstract] [Full Text] [PDF]

				J. Honeychurch, M. J. Glennie, and T. M. Illidge Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells Cancer Res., August 15, 2005; 65(16): 7493 - 7501. [Abstract] [Full Text] [PDF]

				M. Loeffler, J. A. Kruger, and R. A. Reisfeld Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase Cancer Res., June 15, 2005; 65(12): 5027 - 5030. [Abstract] [Full Text] [PDF]

				A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration J. Immunol., March 15, 2005; 174(6): 3317 - 3325. [Abstract] [Full Text] [PDF]

				U. Emmenegger, S. Man, Y. Shaked, G. Francia, J. W. Wong, D. J. Hicklin, and R. S. Kerbel A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens Cancer Res., June 1, 2004; 64(11): 3994 - 4000. [Abstract] [Full Text] [PDF]